Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
Year: 2025
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
Authors: Isabella Claudia Glitza, Suzanne Phillips, Ida John, Roland L. Bassett, Michelle L. Rohlfs, Jessie Richard, Masood Iqbal, Ian E. McCutcheon, Sherise D. Ferguson, Jeffrey S. Weinberg, Golnaz Morad, Adi Diab, Rodabe Navroze Amaria, Jennifer Leigh McQuade, Alexandra Ikeguchi, Hussein A. Tawbi, Elizabeth M. Burton, Michael A. Davies
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Bristol-Myers Squibb
OpenAlex ID: W4410818339